Peripheral Artery Disease (PAD)

It is estimated that approximately 8.5 million people in the United States have Peripheral Artery Disease (PAD), including 12%-20% of individuals older than the age of 60. In animal studies, Zhittya Genesis Medicine's FGF-1 drug triggered new blood vessel growth in the legs of animals with impaired perfusion due to blocked arteries in their leg muscles. PAD is currently an unmet medical need, and Zhittya Genesis Medicine believes it could obtain US FDA designation of a “Medical Breakthrough Therapy” for its drug for this indication.